Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bio-Techne Corp - Common Stock (NQ:TECH)

59.64 +0.83 (+1.42%)
Streaming Delayed Price Updated: 11:08 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Techne Corp - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
5 Health Care Stocks That Are Diving - And May Rally ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More ↗
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022 ↗
 
Via Benzinga
News headline image
Bio-Techne: Q1 Earnings Insights ↗
Bio-Techne (NASDAQ:TECH) reported its Q1 earnings results on Tuesday, November 1, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Recap: Bio-Techne Q4 Earnings ↗
  Bio-Techne (NASDAQ:TECH) reported its Q4 earnings results on Thursday, August 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 10, 2023 ↗
 
Via Benzinga
News headline image
Recap: Bio-Techne Q3 Earnings ↗
Bio-Techne (NASDAQ:TECH) reported its Q3 earnings results on Wednesday, May 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Bio-Techne Clocks 17% Organic Revenue Growth In Q2, Announces $400M Share Buyback ↗
Bio-Techne Corporation (NASDAQ: TECH) has posted Q2 FY22 s 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 2, 2021 ↗
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •... 
Via Benzinga
News headline image
Our 7 Top Biotech Stock Picks for 2023 ↗
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. 
Via InvestorPlace
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 429 stocks made new 52-week lows. 
Via Benzinga
News headline image
Earnings Scheduled For November 1, 2022 ↗
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During Friday's session, 574 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  During Wednesday's session, 265 companies made new 52-week lows. 
Via Benzinga
News headline image
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks ↗
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗
Upgrades 
Via Benzinga
Tackling Recurring Health Conditions Offers Hope to Patients
Palm Beach, FL – June 21, 2022 – FinancialNewsMedia.com News Commentary – Being diagnosed with a health condition can often come as a shock but finding out it can recur is a double blow, particularly... 
Via FinancialNewsMedia
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
On Tuesday, 951 companies hit new 52-week lows. 
Via Benzinga
News headline image
7 Defensive Growth Stocks to Buy for a Shaky Market ↗
These are the best defensive growth stocks to invest in now. Each of these can make great investments if/when the market sours. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022 ↗
 
Via Benzinga
News headline image
7 Superior Stocks That Smart Investors Will Buy on the Dip ↗
The recent sell-off presents long-term investors with many robust stocks to buy on the dip. These seven provide a start. 
Via InvestorPlace
News headline image
10 Biggest Price Target Changes For Wednesday ↗
Keybanc lifted the price target for Alphabet Inc. (NASDAQ: GOOGL) from $3,090 to $3,400. Alphabet shares surged 11% to $3,055.00 in pre-market trading. 
Via Benzinga
News headline image
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Bio-Techne Stock In The Last 5 Years ↗
Bio-Techne (NASDAQ:TECH) has outperformed the market over the past 5 years by 17.84% on an annualized basis. Buying $1,000.00 In TECH: 5 years ago, an investor could have... 
Via Benzinga
News headline image
Bio-Techne Corporation (TECH) Q1 2022 Earnings Call Transcript ↗
TECH earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
News headline image
Bio-Techne's Earnings: A Preview ↗
Bio-Techne (NASDAQ:TECH) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.